DMD Research News
Each year at La Force DMD, we select the most interesting and promising research for Duchenne muscular dystrophy (DMD) to support.
We live in an era of ultra-fast change, where science and technology are working together more than they ever have. This is especially true for DMD, which has seen significant strides in genetic research.
Before we fund projects, it’s crucial to ensure that the research protocols are ethical and that the preliminary results of the research are auspicious. With the help of the Duchenne Alliance, we consult experts in the field of genetics to ensure that projects have real potential to advance the treatment of DMD.
This year, La Force is participating in three research projects that we believe are extremely promising.
DMD Research Funded in 2016 – 2017 – 2018
- Project 1 – Osteoprotegerin
- Project 2 – CRISPR/Cas9
How can I find out about clinical trials?
Enlisting in a DMD registry can guide the medical researchers who plan clinical trials of new therapies to you. A registry can help these scientists to identify children with DMD who live near a particular research centre and contact them about upcoming clinical trials.
Clinical Trials Simplified and La Force Dystrophie Musculaire de Duchenne (La Force DMD) join forces to accelerate the development of new therapies for DMD
Clinical Trials Simplified (CTS) and La Force Dystrophie Musculaire de Duchenne (La Force DMD) announce the establishment of a joint partnership to help patients suffering from DMD across the province find clinical trials. This partnership aims to facilitate access to clinical trials for patients with DMD and to accelerate the development of new therapies for DMD. Learn more here.
Registries
Learn more about registries here.
Learn more about:
CRISPR/CAS9 UNDERSTANDING CRISPR/CAS9 WITH JACQUES P. TREMBLAY
CRISPR/CAS9 CRISPR & DUCHENNE MUSCULAR DYSTROPHY
EDASALONEXENT POSITIVE RESULTS AND NO SIDE EFFECTS
EDASALONEXENT THE POTENTIAL TO MODIFY DMD
EDASALONEXENT PHASE 3 POLARISDMD TRIAL OF EDASALONEXENT IS NOW OPEN FOR ENROLLMENT IN CANADA
DEFLAZACORT DEFLAZACORT OVER PREDNISONE/PREDNISOLONE?
EXONDYS® NEGATIVE OPINION FOR EXONDYS® IN EUROPE
GENE TRANSFER SGT-001 SOLID BIOSCIENCES ANNOUNCES NEW PRECLINICAL DATA ABOUT GENE TRANSFER
GENE TRANSFER SGT-001 SOLID BIOSCIENCES INITIATES CLINICAL TRIAL FOR GENE TRANSFER
TRANSLARNA™ (ATALUREN) POSITIVE NEWS FOR TRANSLARNA™ (ATALUREN)
TRANSLARNA™ (ATALUREN) A PROMISING TREATMENT FOR DMD
TRANSLARNA™ (ATALUREN) CLINICAL TRIAL OF ATALUREN IN CANADA
STAT3 A NEW RESEARCH TO TREAT DMD
CAP-1002 CAPRICOR INITIATES HOPE-2 CLINICAL TRIAL
GOLODIRSEN NEW DMD EXON-SKIPPING THERAPY ON THE WAY
GOLODIRSEN NEW DRUG FOR DMD BEING REVIEWED BY THE FDA
GOLODIRSEN NEWS ABOUT GOLODIRSEN, SKIPPING EXON 53
CASIMERSEN AND GOLODIRSEN SAREPTA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM THE ESSENCE STUDY
IDEBENONE IDEBENONE FOR DUCHENNE MUSCULAR DYSTROPHY
PAMREVLUMAB FIBROGEN RECEIVES ORPHAN DRUG DESIGNATION FOR PAMREVLUMAB